Strategies to improve implementation of medications for opioid use disorder reported by veterans involved in the legal system: A qualitative study

2021 ◽  
Vol 129 ◽  
pp. 108353
Author(s):  
Erica Morse ◽  
Ingrid A. Binswanger ◽  
Emmeline Taylor ◽  
Caroline Gray ◽  
Matthew Stimmel ◽  
...  
2020 ◽  
Vol 35 (9) ◽  
pp. 2529-2536
Author(s):  
Andrea K. Finlay ◽  
Erica Morse ◽  
Matthew Stimmel ◽  
Emmeline Taylor ◽  
Christine Timko ◽  
...  

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Elizabeth C. Saunders ◽  
Sarah K. Moore ◽  
Olivia Walsh ◽  
Stephen A. Metcalf ◽  
Alan J. Budney ◽  
...  

Abstract Background Increasingly, treatment for opioid use disorder (OUD) is offered in integrated treatment models addressing both substance use and other health conditions within the same system. This often includes offering medications for OUD in general medical settings. It remains uncertain whether integrated OUD treatment models are preferred to non-integrated models, where treatment is provided within a distinct treatment system. This study aimed to explore preferences for integrated versus non-integrated treatment models among people with OUD and examine what factors may influence preferences. Methods This qualitative study recruited participants (n = 40) through Craigslist advertisements and flyers posted in treatment programs across the United States. Participants were 18 years of age or older and scored a two or higher on the heroin or opioid pain reliever sections of the Tobacco, Alcohol, Prescription Medications, and Other Substances (TAPS) Tool. Each participant completed a demographic survey and a telephone interview. The interviews were coded and content analyzed. Results While some participants preferred receiving OUD treatment from an integrated model in a general medical setting, the majority preferred non-integrated models. Some participants preferred integrated models in theory but expressed concerns about stigma and a lack of psychosocial services. Tradeoffs between integrated and non-integrated models were centered around patient values (desire for anonymity and personalization, fear of consequences), the characteristics of the provider and setting (convenience, perceived treatment effectiveness, access to services), and the patient-provider relationship (disclosure, trust, comfort, stigma). Conclusions Among this sample of primarily White adults, preferences for non-integrated versus integrated OUD treatment were mixed. Perceived benefits of integrated models included convenience, potential for treatment personalization, and opportunity to extend established relationships with medical providers. Recommendations to make integrated treatment more patient-centered include facilitating access to psychosocial services, educating patients on privacy, individualizing treatment, and prioritizing the patient-provider relationship. This sample included very few minorities and thus findings may not be fully generalizable to the larger population of persons with OUD. Nonetheless, results suggest a need for expansion of both OUD treatment in specialty and general medical settings to ensure access to preferred treatment for all.


2017 ◽  
Vol 39 (1) ◽  
pp. 52-58 ◽  
Author(s):  
Randi Sokol ◽  
Chiara Albanese ◽  
Deviney Chaponis ◽  
Jessica Early ◽  
George Maxted ◽  
...  

2018 ◽  
Vol 8 (12) ◽  
pp. 761-768 ◽  
Author(s):  
Mary Beth Howard ◽  
Elisha Wachman ◽  
Emily M. Levesque ◽  
Davida M. Schiff ◽  
Caroline J. Kistin ◽  
...  

2021 ◽  
pp. appi.ps.2020005
Author(s):  
Austin S. Kilaru ◽  
Su Fen Lubitz ◽  
Jessica Davis ◽  
Whitney Eriksen ◽  
Sari Siegel ◽  
...  

2019 ◽  
Vol 97 ◽  
pp. 28-40 ◽  
Author(s):  
Benjamin J. Oldfield ◽  
Nicolas Muñoz ◽  
Nicholas Boshnack ◽  
Robert Leavitt ◽  
Mark P. McGovern ◽  
...  

2020 ◽  
Vol 10 (4) ◽  
pp. 226 ◽  
Author(s):  
Alessandra Matzeu ◽  
Rémi Martin-Fardon

Prescription opioids are potent analgesics that are used for clinical pain management. However, the nonmedical use of these medications has emerged as a major concern because of dramatic increases in abuse and overdose. Therefore, effective strategies to prevent prescription opioid use disorder are urgently needed. The orexin system has been implicated in the regulation of motivation, arousal, and stress, making this system a promising target for the treatment of substance use disorder. This review discusses recent preclinical studies that suggest that orexin receptor blockade could be beneficial for the treatment of prescription opioid use disorder.


2020 ◽  
Vol 50 (4) ◽  
pp. 550-565 ◽  
Author(s):  
Philip R. Kavanaugh ◽  
Katherine McLean

Drawing on a multisite sample of 40 persons who sell, share, or use diverted buprenorphine to manage opioid use disorder, in this study we describe why individuals seek to obtain buprenorphine outside of formal treatment contexts, and between-site variation regarding their motives and means. Findings indicate that both the provision and purchase of diverted buprenorphine support user-defined risk minimization strategies to avoid withdrawal, reduce heroin use, and satiate opioid cravings in periods of lowered tolerance. We also found that a subset of the sample used buprenorphine recreationally, and that it functioned to extend or augment illicit drug use careers. Implications of the findings are discussed in light of federal and state drug control and treatment policies.


Sign in / Sign up

Export Citation Format

Share Document